Epoetin Alfa (Erythropoietin)

Epoetin alfa is a recombinant human erythropoietin used to stimulate red-cell production in selected nonregenerative anemias. Its best-established veterinary application is anemia associated with chronic kidney disease in dogs and cats. It replaces deficient erythropoietic signaling, with the clinical response depending on marrow function and availability of substrates for red-cell synthesis.

Group

Erythropoiesis-stimulating agent

Mechanism of Action

Epoetin alfa binds erythropoietin receptors on erythroid progenitor cells in bone marrow. Receptor activation promotes cell survival, proliferation and maturation, increasing production of reticulocytes and subsequently circulating red blood cells. In chronic kidney disease, it compensates for inadequate renal erythropoietin output. The rise in red-cell mass develops through new cell production rather than an immediate transfusion-like effect.

Dose Rates

Dog

Use / stage	Dose	Route	Schedule	Instructions
Renal anemia induction	Reference only	SC		35 or 50 IU/kg three times weekly, adjusted to hematocrit; source upper total 400 IU/kg per week. Weekly cap and calendar schedule require dedicated protocol support.

Cat

Use / stage	Dose	Route	Schedule	Instructions
Renal anemia induction	Reference only	SC		100 IU/kg three times weekly until target PCV, then reduce to twice weekly and later once weekly.
Renal anemia maintenance	Reference only	SC		75–100 IU/kg twice weekly, or adjusted to once weekly after stabilization; do not convert twice weekly into an assumed fixed-hour schedule.

Ferret

Use / stage	Dose	Route	Schedule	Instructions
Anemia treatment	Reference only	IM		50–150 IU/kg three times weekly; reduce to once weekly if red-cell indices improve sufficiently. Calendar-based induction is not an exact fixed-hour interval.

Rabbit

Use / stage	Dose	Route	Schedule	Instructions
Anemia treatment — Initial	50–150 mg/kg	SC	Every 48–72 h	Continue until PCV normalizes, then use the maintenance course.
Anemia treatment — Maintenance	50–150 mg/kg	SC	Every 168 h	Continue for at least four weeks after PCV normalization.

Indications

Treatment of clinically significant nonregenerative anemia associated with chronic kidney disease in dogs and cats.
Specialist treatment of selected other hypoproliferative anemias with a suspected erythropoietin-responsive component, including some disease- or treatment-associated anemias; veterinary evidence is limited.

Contraindications

Stop with suspected antibody-mediated aplasia or systemic hypersensitivity.

Adverse effects

Pure red cell aplasia from cross-reacting antibodies
Seizures and injection reactions

Preparations

Preparation	Form	Strength	Route
Epoetin alfa 2000 IU/mL	Injection	2000 IU / mL	SC
Epoetin alfa 3000 IU/mL	Injection	3000 IU / mL	SC
Epoetin alfa 4000 IU/mL	Injection	4000 IU / mL	SC
Epoetin alfa 10000 IU/mL	Injection	10000 IU / mL	SC
Epoetin alfa 20000 IU/mL	Injection	20000 IU / mL	SC
Epoetin alfa 40000 IU/mL	Injection	40000 IU / mL	SC

Monitoring and Administration

Monitor hematocrit, reticulocytes, iron status and blood pressure. Typical target PCV is approximately 30–34%, with feline protocols sometimes targeting 30–40%.

Ensure iron adequacy. Darbepoetin is often preferred for prolonged treatment because of the antibody risk.

Store Epogen at 2–8°C, protected from light; do not freeze or shake. Discard single-use vial remainder.